人呼吸道合胞病毒感染的预防和治疗研究进展

doi:10.19586/j.2095-2341.2023.0140

生物技术进展 ›› 2024, Vol. 14 ›› Issue (1): 26-34.DOI: 10.19586/j.2095-2341.2023.0140

• 生物制品研发与技术专题 • 上一篇下一篇

人呼吸道合胞病毒感染的预防和治疗研究进展

吕娜¹(), 李岩异¹, 马祝青²()

^1.华北制药金坦生物技术股份有限公司，石家庄 050035
^2.山东博安生物技术股份有限公司，山东烟台 264003

收稿日期:2023-10-30 接受日期:2023-11-29 出版日期:2024-01-25 发布日期:2024-02-05
通讯作者: 马祝青
作者简介:吕娜 E-mail: chuanxue007@163.com；

Advances on Prevention and Treatment of Human Respiratory Syncytial Virus

Na LYU¹(), Yanyi LI¹, Zhuqing MA²()

^1.North China Pharmaceutical Jintan Biotechnology Co. ，Ltd. ，Shijiazhuang 050035，China
^2.Shandong Boan Biotechnology Co. ，Ltd. ，Shandong Yantai 264003，China

Received:2023-10-30 Accepted:2023-11-29 Online:2024-01-25 Published:2024-02-05
Contact: Zhuqing MA

摘要/Abstract

摘要：

呼吸道合胞病毒（respiratory syncytial virus, RSV）会引起呼吸道和肺部感染，尤其是婴幼儿和老人，容易出现严重感染。尽管RSV感染对医疗保健产生了全球性影响，目前仍以支持性的治疗为主。在过去的几十年中，随着对 RSV 发病机制和免疫病理学的了解不断加深，RSV的预防策略取得了重大进步。自1966年 RSV 疫苗首次试验以来已经过去50多年，目前有两种RSV疫苗获批上市。综述了当前RSV感染的治疗方案（包括RSV 特异性和非特异性）以及RSV疫苗的研发进展，以期为RSV的治疗及疫苗的研发提供参考。

关键词: 呼吸道合胞病毒（RSV）, 单克隆抗体, 抗病毒, 疫苗

Abstract:

Respiratory syncytial virus （RSV） is a leading cause of respiratory and lung infections， especially in young children and the elderly， which are prone to serious infections. Despite the global impact of RSV infection on healthcare， the current therapy is still mostly supportive. Over the past few decades， our understanding of the pathogenesis and immunopathology of RSV had evolved， leading to significant advances in RSV prevention strategies. More than 50 years have passed since the RSV vaccine was first trialed in 1966， and two RSV vaccines have been approved. In this paper， current treatment options for RSV infection （including RSV-specific and non-specific） and the development progress of different RSV prevention vaccines were reviewed， which was expected to provide reference for the treatment and vaccines research and development of RSV.

Key words: respiratory syncytial virus （RSV）, monoclonal antibodies, antiviral, vaccine

中图分类号:

Q939.47

吕娜, 李岩异, 马祝青. 人呼吸道合胞病毒感染的预防和治疗研究进展[J]. 生物技术进展, 2024, 14(1): 26-34.

Na LYU, Yanyi LI, Zhuqing MA. Advances on Prevention and Treatment of Human Respiratory Syncytial Virus[J]. Current Biotechnology, 2024, 14(1): 26-34.

图/表 1

参考文献 74

1	NAM H H, ISON M G. Respiratory syncytial virus infection in adults[J/OL]. BMJ, 2019, 366: l5021[2023-10-20]. .
2	MATIAS G, TAYLOR R, HAGUINET F, et al.. Estimates of hospitalization attributable to influenza and RSV in the US during 1997-2009, by age and risk status[J/OL]. BMC Public Health, 2017, 17(1): 271[2023-10-20]. .
3	BLANKEN M O, ROVERS M M, MOLENAAR J M, et al.. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants[J]. N. Engl. J. Med., 2013, 368(19): 1791-1799.
4	BINNS E, TUCKERMAN J, LICCIARDI P V, et al.. Respiratory syncytial virus, recurrent wheeze and asthma: a narrative review of pathophysiology, prevention and future directions[J]. J. Paediatr. Child. Health, 2022, 58(10): 1741-1746.
5	ZHANG L, PEEPLES M E, BOUCHER R C, et al.. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology[J]. J. Virol., 2002, 76(11): 5654-5666.
6	MCLELLAN J S, YANG Y, GRAHAM B S, et al.. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes[J]. J. Virol., 2011, 85(15): 7788-7796.
7	YEO K T, YUNG C F, KHOO P C, et al.. Effectiveness of palivizumab against respiratory syncytial virus hospitalization among preterm infants in a setting with year-round circulation[J]. J. Infect. Dis., 2021, 224(2): 279-287.
8	ALANSARI K, TOAIMAH F H, ALMATAR D H, et al.. Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial[J/OL]. Pediatrics, 2019, 143(3): e20182308[2023-10-20]. .
9	CINGOZ O. Motavizumab[J]. mAbs, 2009, 1(5): 439-442.
10	RAMILO O, LAGOS R, SÁEZ-LLORENS X, et al.. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness[J]. Pediatr. Infect. Dis. J., 2014, 33(7): 703-709.
11	PLOCK N, LOMMERSE J, MAAS B M, et al.. Predicting RSV efficacy for MK-1654 in temperate and tropical climates using MBMA and clinical trial simulation to account for seasonal differences in RSV force-of-infection[J]. Open Forum. Infect. Dis., 2021, 8(S1): 597-598.
12	GRIFFIN M P, KHAN A A, ESSER M T, et al.. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults[J]. Antimicrob. Agents Chemother., 2017, 61(3): 01714-01716.
13	European Medicines Agency. Nirsevimab (Beyfortus): EU summary of product characteristics[EB/OL].[2023-10-20]. .
14	DOMACHOWSKE J B, KHAN A A, ESSER M T, et al.. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants[J]. Pediatr. Infect. Dis. J., 2018, 37(9): 886-892.
15	GRIFFIN M P, YUAN Y, TAKAS T, et al.. Single-dose nirsevimab for prevention of RSV in preterm infants[J]. N. Engl. J. Med., 2020, 383(5): 415-425.
16	PRINCE G A, HEMMING V G, HORSWOOD R L, et al.. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat[J]. Virus Res., 1985, 3(3): 193-206.
17	SÁEZ-LLORENS X, MORENO M T, RAMILO O, et al.. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection[J]. Pediatr. Infect. Dis. J., 2004, 23(8): 707-712.
18	SANDERS S L, AGWAN S, HASSAN M, et al.. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection[J/OL]. Cochrane Database Syst. Rev., 2019, 8: CD009417[2023-10-20]. .
19	DOMACHOWSKE J B, ANDERSON E J, GOLDSTEIN M. The future of respiratory syncytial virus disease prevention and treatment[J]. Infect. Dis. Ther., 2021, 10(1): 47-60.
20	SINCLAIR S M, JONES J K, MILLER R K, et al.. The ribavirin pregnancy registry: an interim analysis of potential teratogenicity at the mid-point of enrollment[J]. Drug Saf., 2017, 40(12): 1205-1218.
21	SHULTS R A, BARON S, DECKER J, et al.. Health care worker exposure to aerosolized ribavirin: biological and air monitoring[J]. J. Occup. Environ. Med., 1996, 38(3): 257-263.
22	BURROWS F, CARLOS L, MARRIOTT D, et al.. Oral ribavirin is a cost-effective alternative to intravenous ribavirin for respiratory syncytial virus (RSV) infection after lung transplantation (LTx)[J]. J. Heart Lung Transplant, 2013, 32(4S): S109.
23	TEJADA S, MARTINEZ-REVIEJO R, KARAKOC H N, et al.. Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis[J]. Adv. Ther., 2022, 39(9): 4037-4051.
24	MED B N L. Identifier: NCT 04225897. A study in infants with RSV LRTI to evaluate RV521 (REVIRAL 1)[EB/OL]. [2023-10-20]. .
25	MED B N L. Identifier: NCT04231968. Study ofAKA0529 in Chinese Infants Hospitalized with RSV (AirFLO)[EB/OL]. [2023-10-20]. .
26	HISLOP A A, HAWORTH S G. Airway size and structure in the normal fetal and infant lung and the effect of premature delivery and artificial ventilation[J]. Am. Rev. Respir. Dis., 1989, 140(6): 1717-1726.
27	LINSSEN R S N, MA J, BEM R A, et al.. Rational use of mucoactive medications to treat pediatric airway disease[J]. Paediatr. Respir. Rev., 2020, 36: 8-14.
28	GADOMSKI A M, SCRIBANI M B. Bronchodilators for bronchiolitis[J/OL]. Cochrane Database Syst Rev, 2014(6): CD001266[2023-10-20]. .
29	KRILOV L R. Respiratory syncytial virus disease: update on treatment and prevention[J]. Expert Rev. Anti. Infect. Ther., 2011, 9(1): 27-32.
30	O'DONNELL S. Experimental and clinical pharmacology: leukotrienes-biosynthesis and mechanisms of action[J]. Aust. Prescr., 1999, 22(3): 55-57.
31	LIU F, OUYANG J, SHARMA A N, et al.. Leukotriene inhibitors for bronchiolitis in infants and young children[J/OL]. Cochrane Database Syst. Rev., 2015(3): CD010636[2023-10-20]. .
32	MERKUS P J, DE HOOG M, VAN GENT R, et al.. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis[J]. Eur. Respir. J., 2001, 18(4): 734-737.
33	THORNBY K A, JOHNSON A, AXTELL S. Dornase Alfa for non-cystic fibrosis pediatric pulmonary atelectasis[J]. Ann.Pharmacother., 2014, 48(8): 1040-1049.
34	BOOGAARD R, HULSMANN A R, VAN VEEN L, et al.. Recombinant human deoxyribonuclease in infants with respiratory syncytial virus bronchiolitis[J]. Chest, 2007, 131(3): 788-795.
35	ANNABELLE E, CHU I W, CRAIG M,et al..Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months[J]. Cochrane Database Syst. Rev., 2012, 11(11):1-26.
36	KELLNER J D, OHLSSON A, GADOMSKI A M, et al.. Efficacy of bronchodilator therapy in bronchiolitis. A meta-analysis[J]. Arch. Pediatr. Adolesc. Med., 1996, 150(11): 1166-1172.
37	RODRÍGUEZ-MARTÍNEZ C E, NINO G, CASTRO-RODRIGUEZ J A, et al.. For which infants with viral bronchiolitis could it be deemed appropriate to use albuterol, at least on a therapeutic trial basis?[J]. Allergol. Immunopathol. Madr., 2021, 49(1): 153-158.
38	SATHE N A, KRISHNASWAMI S, ANDREWS J, et al.. Pharmacologic agents that promote airway clearance in hospitalized subjects: a systematic review[J]. Respir. Care., 2015, 60(7): 1061-1070.
39	MATA M, MORCILLO E, GIMENO C, et al.. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type Ⅱ epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)[J]. Biochem. Pharmacol., 2011, 82(5): 548-555.
40	NAZ F, RAZA A B, IJAZ I, et al.. Effectiveness of nebulized N-acetylcysteine solution in children with acute bronchiolitis[J]. J. Coll. Physicians. Surg. Pak., 2014, 24(6): 408-411.
41	SOMERS C C, AHMAD N, MEJIAS A, et al.. Effect of dexamethasone on respiratory syncytial virus-induced lung inflammation in children: results of a randomized, placebo controlled clinical trial[J]. Pediatr. Allergy. Immunol., 2009, 20(5): 477-485.
42	FERNANDES R M, BIALY L M, VANDERMEER B, et al.. Glucocorticoids for acute viral bronchiolitis in infants and young children[J/OL]. Cochrane Database Syst. Rev., 2013(6): CD004878[2023-10-20]. .
43	ALANSARI K, SAKRAN M, DAVIDSON B L, et al.. Oral dexamethasone for bronchiolitis: a randomized trial[J]. Pediatrics, 2013, 132(4): 810-816.
44	DAVISKAS E, ANDERSON S D, GONDA I, et al.. Inhalation of hypertonic saline aerosolenhances mucociliary clearance in asthmatic and healthy subjects[J]. Eur. Respir. J. 1996, 9(4):725-732.
45	KELLETT F, REDFERN J, NIVEN R M. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis[J]. Respir. Med., 2005, 99(1): 27-31.
46	WARK P A, MCDONALD V, JONES A P. Nebulised hypertonic saline for cystic fibrosis[J/OL]. Cochrane Database Syst. Rev., 2005(3): CD001506[2023-10-20]. .
47	MANDELBERG A, AMIRAV I. Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale[J]. Pediatr. Pulmonol., 2010, 45(1): 36-40.
48	DALT L D A, BRESSAN S, MARTINOLLI F, et al.. Treatment of bronchiolitis: state of the art[J]. Early Hum. Dev., 2013, 89(S1): S31-S36.
49	MANDELBERG A, TAL G, WITZLING M, et al.. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis[J]. Chest, 2003, 123(2): 481-487.
50	FABER T E, KAMPS A W, SJOERDSMA M H, et al.. Computerized assessment of wheezing in children with respiratory syncytial virus bronchiolitis before and after hypertonic saline nebulization[J]. Respir. Care., 2015, 60(9): 1252-1256.
51	SARRELL E M, TAL G, WITZLING M, et al.. Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms[J]. Chest, 2002, 122(6): 2015-2020.
52	ZHANG L, GUNTHER C B, FRANCO O S, et al.. Impact of hypertonic saline on hospitalization rate in infants with acute bronchiolitis: a meta-analysis[J]. Pediatr. Pulmonol., 2018, 53(8): 1089-1095.
53	MORIKAWA Y, MIURA M, FURUHATA M Y, et al.. Nebulized hypertonic saline in infants hospitalized with moderately severe bronchiolitis due to RSV infection: a multicenter randomized controlled trial[J]. Pediatr. Pulmonol., 2018, 53(3): 358-365.
54	JAQUET-PILLOUD R, VERGA M E, RUSSO M, et al.. Nebulised hypertonic saline in moderate-to-severe bronchiolitis: a randomised clinical trial[J]. Arch. Dis. Child., 2020, 105(3): 236-240.
55	HARTLING L, WIEBE N, RUSSELL K, et al.. Epinephrine for bronchiolitis[J/OL]. Cochrane Database Syst. Rev., 2004(1): CD003123[2023-10-20]. .
56	PINTO L A, PITREZ P M, LUISI F, et al.. Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial[J]. J. Pediatr., 2012, 161(6): 1104-1108.
57	TAL G, CESAR K, ORON A, et al.. Hypertonic saline/epinephrine treatment in hospitalized infants with viral bronchiolitis reduces hospitalization stay: 2 years experience[J]. Isr. Med. Assoc. J., 2006, 8(3): 169-173.
58	FLORES-GONZÁLEZ J C, MATAMALA-MORILLO M A, RODRÍGUEZ-CAMPOY P, et al.. Epinephrine improves the efficacy of nebulized hypertonic saline in moderate bronchiolitis: a randomised clinical trial[J/OL]. PLoS ONE, 2015, 10(11): e0142847[2023-10-20]. .
59	GOLDBART A, LAVIE M, LUBETZKY R, et al.. Inhaled nitric oxide for the treatment of acute bronchiolitis: a multicenter randomized controlled clinical trial to evaluate dose response[J]. Ann. Am. Thorac. Soc., 2023, 20(2): 236-244.
60	POLACK F P, TENG M N, COLLINS P L, et al.. A role for immune complexes in enhanced respiratory syncytial virus disease[J]. J. Exp. Med., 2002, 196(6): 859-865.
61	GRAHAM B S. Immunological goals for respiratory syncytial virus vaccine development[J]. Curr. Opin. Immunol., 2019, 59: 57-64.
62	YAMIN D, JONES F K, DEVINCENZO J P, et al.. Vaccination strategies against respiratory syncytial virus[J]. Proc. Natl. Acad. Sci. USA, 2016, 113(46): 13239-13244.
63	COLLINS P L, MURPHY B R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics[J]. Proc. Am. Thorac. Soc., 2005, 2(2): 166-173.
64	MCFARLAND E J, KARRON R A, MURESAN P, et al.. Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children[J]. J. Infect. Dis., 2020, 221(4): 534-543.
65	MCFARLAND E J, KARRON R A, MURESAN P, et al.. Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with small hydrophobic noncoding region is highly immunogenic in children[J]. J. Infect. Dis., 2020, 221(12): 2050-2059.
66	SHANG Z F, TAN S G, MA D L. Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies[J]. Int. J. Biol. Sci.,2021,17(14): 4073-4091.
67	JENKINS T, WANG R, HARDER O, et al.. A novel live attenuated respiratory syncytial virus vaccine candidate with mutations in the L protein SAM binding site and the G protein cleavage site is protective in cotton rats and a Rhesus macaque[J]. J. Virol., 2021, 95(3):1568-1520.
68	PAPI A, ISON M G, LANGLEY J M, et al.. Respiratory syncytial virus prefusion F protein vaccine in older adults[J]. N. Engl. J. Med., 2023, 388(7): 595-608.
69	MOGHADAS A M, SHOUKAT A, BAWDEN C E, et al.. Cost-effectiveness of prefusion F protein-based vaccines against respiratory syncytial virus disease for older adults in the United States[J/OL]. Clin. Infect. Dis.,2023:ciad658[2023-11-20]. .
70	MADHI S A, POLACK F P, PIEDRA P A, et al.. Respiratory syncytial virus vaccination during pregnancy and effects in infants[J]. N. Engl. J. Med., 2020, 383(5): 426-439.
71	ANDREANO E, PACIELLO I, BARDELLI M, et al.. The respiratory syncytial virus (RSV) prefusion F-protein functional antibody repertoire in adult healthy donors[J/OL]. EMBO Mol. Med., 2021, 13(6): e14035[2023-10-20]. .
72	SWANSON K A, RAINHO-TOMKO J N, WILLIAMS Z P, et al.. A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain[J/OL]. Sci. Immunol., 2020, 5(47): eaba6466[2023-10-20]. .
73	ESPESETH A S, CEJAS P J, CITRON M P, et al.. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection[J/OL]. NPJ Vaccines, 2020, 5: 16[2023-10-20]. .
74	MODERNA. Moderna announces clinical progress from its industry-leading mRNA vaccine franchise and continues investments to accelerate pipeline development[EB/OL].[2023-10-20]. .

疫苗类型	疫苗名称	目标人群	研发公司	临床试验阶段	临床试验号
减毒活疫苗	LID∆M2-2/1030s	婴幼儿	NIAID (Medi)	Ⅰ期	NCT02794870
	RSV ΔNS2 Δ1313 I1314L	婴幼儿	NIAID (Medi)	Ⅰ/Ⅱ期	NCT01893554
	RSV 6120/Δ NS2/1030s	婴幼儿	NIAID (Sanofi)	Ⅰ期	NCT03387137
	RSV 6120/ΔNS1	婴幼儿	NIAID (Sanofi)	Ⅰ期	NCT03596801
	MV-012-968	婴幼儿	Meissa Vaccines	Ⅰ期	NCT04909021
	CodaVax-RSV	老年人	Codagenix, Inc	Ⅰ期	NCT04295070
蛋白/亚单位疫苗	BARS13	老年人	Advaccine (Suzhou)	Ⅱ期	NCT04681833
	RSV F DS-Cav1	成年人	NIAID	Ⅰ期	NCT03049488
	VN-0200	老年人	Daiichi Sankyo Co., Ltd.	Ⅱ期	NCT05547087
	IVX-A12 (RSV/hMPV)	老年人	Icosavax	Ⅱ期	NCT05903183
	IVX-121 (RSV)	老年人	Icosavax	Ⅰ期	2020-003633-38
mRNA疫苗	mRNA-1345	婴幼儿	Moderna	Ⅰ期	NCT04528719
mRNA疫苗	mRNA LNP	老年人	Sanofi	Ⅰ期	NCT05639894

疫苗类型	疫苗名称	目标人群	研发公司	临床试验阶段	临床试验号
减毒活疫苗	LID∆M2-2/1030s	婴幼儿	NIAID (Medi)	Ⅰ期	NCT02794870
	RSV ΔNS2 Δ1313 I1314L	婴幼儿	NIAID (Medi)	Ⅰ/Ⅱ期	NCT01893554
	RSV 6120/Δ NS2/1030s	婴幼儿	NIAID (Sanofi)	Ⅰ期	NCT03387137
	RSV 6120/ΔNS1	婴幼儿	NIAID (Sanofi)	Ⅰ期	NCT03596801
	MV-012-968	婴幼儿	Meissa Vaccines	Ⅰ期	NCT04909021
	CodaVax-RSV	老年人	Codagenix, Inc	Ⅰ期	NCT04295070
蛋白/亚单位疫苗	BARS13	老年人	Advaccine (Suzhou)	Ⅱ期	NCT04681833
	RSV F DS-Cav1	成年人	NIAID	Ⅰ期	NCT03049488
	VN-0200	老年人	Daiichi Sankyo Co., Ltd.	Ⅱ期	NCT05547087
	IVX-A12 (RSV/hMPV)	老年人	Icosavax	Ⅱ期	NCT05903183
	IVX-121 (RSV)	老年人	Icosavax	Ⅰ期	2020-003633-38
mRNA疫苗	mRNA-1345	婴幼儿	Moderna	Ⅰ期	NCT04528719
mRNA疫苗	mRNA LNP	老年人	Sanofi	Ⅰ期	NCT05639894

[1]	焦红燕, 李国超, 常亮, 李岩异, 翟丽丽. 诺如病毒疫苗研究概况[J]. 生物技术进展, 2024, 14(1): 17-25.
[2]	蔚丹, 马云龙, 万方, 武建强. mRNA疫苗的研究及应用进展[J]. 生物技术进展, 2023, 13(4): 492-498.
[3]	高朗, 于思雪, 袁春森, 单志伟, 赵鹏翔. 黏蛋白在肿瘤免疫治疗中的研究进展[J]. 生物技术进展, 2023, 13(3): 390-398.
[4]	周水娟, 郭忠建. 双分子荧光互补技术在动物病毒中的研究进展[J]. 生物技术进展, 2022, 12(6): 825-836.
[5]	李文桂, 陈雅棠. 重组金丝雀痘病毒载体疫苗研制进展[J]. 生物技术进展, 2022, 12(1): 36-43.
[6]	李丹, 宋浩志, 高维崧, 刘兴健, 张志芳, 李轶女. 小反刍兽疫病毒H蛋白的原核表达及免疫原性测定[J]. 生物技术进展, 2021, 11(6): 770-776.
[7]	张博慧,贾戴辉,程倩,许俊彦,邵喆,黄应峰. 利用N糖苷酶F对单克隆抗体N糖酶解条件的优化[J]. 生物技术进展, 2021, 11(2): 214-222.
[8]	王欢,牛昆,江一帆,董静. 重组单克隆抗体电荷异质性和工艺调控[J]. 生物技术进展, 2020, 10(5): 456-462.
[9]	姚舜禹,张丽琳. 新城疫疫苗研究进展[J]. 生物技术进展, 2020, 10(5): 470-478.
[10]	孙卉,张春义,姜凌. 硒与叶酸在抗病毒治疗中的作用及其在植物中的应用前景分析[J]. 生物技术进展, 2020, 10(5): 487-494.
[11]	杨鑫,宋浩志,刘兴健,李轶女,张志芳. 鸡κ干扰素在家蚕杆状病毒表达系统中的表达及其抗病毒活性检测[J]. 生物技术进展, 2020, 10(3): 251-255.
[12]	王先翔,赵泽,王朋,刘兴健,胡小元,张志芳,李轶女,房岭丽,叶爱华. 羊λ3干扰素在家蚕杆状病毒表达系统中的表达及其抗病毒活性检测[J]. 生物技术进展, 2019, 9(5): 502-508.
[13]	赵云霞,江魁,郭爱英,李景艳. 1型肺炎兔抗血清的制备及其在多糖含量检测中的质控研究[J]. 生物技术进展, 2019, 9(4): 416-421.
[14]	刘梦昱,谢飞,张鑫,赵鹏翔,. 胶质母细胞瘤免疫治疗研究进展[J]. 生物技术进展, 2019, 9(3): 223-230.
[15]	魏珍珍,刘兴健,王朋,张志芳,易咏竹. 自组装铁蛋白在纳米疫苗领域的应用进展[J]. 生物技术进展, 2019, 9(3): 240-245.

人呼吸道合胞病毒感染的预防和治疗研究进展

Advances on Prevention and Treatment of Human Respiratory Syncytial Virus

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 74

相关文章 15

编辑推荐

Metrics

本文评价